Jack Z. Gougoutas

Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists

A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.

N-Aryl-oxazolidin-2-imine Muscle Selective Androgen Receptor Modulators Enhance Potency through Pharmacophore Reorientation

A novel selective androgen receptor modulator (SARM) scaffold was discovered as a byproduct obtained during synthesis of our earlier series of imidazolidin-2-ones. The resulting oxazolidin-2-imines are among the most potent SARMs known, with many analogues exhibiting sub-nM in vitro potency in binding and functional assays. Despite the potential for hydrolytic instability at gut pH, compounds of the present class showed good oral bioavailability and were highly active in a standard rodent pharmacological model.

Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.

Conformational restriction of open chain analogs with a more polar tetrahydro-1,3-oxazin-2-one spacer led to the identification of potent urea-based CCR3 antagonists that exhibited excellent selectivity over binding to CYP2D6. The in vitro binding and eosinophil shape change data are presented. Compound 19b exhibited similar selectivity and potency to our development candidate BMS-639623.

Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists

Modification of a phenolic lead structure based on lessons learned from increasing the potency of steroidal glucocorticoid agonists lead to the discovery of exceptionally potent, nonsteroidal, indazole GR agonists. SAR was developed to achieve good selectivity against other nuclear hormone receptors with the ultimate goal of achieving a dissociated GR agonist as measured by human in vitro assays. The specific interactions by which this class of compounds inhibits GR was elucidated by solving an X-ray co-crystal structure.

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.

An unexpected by-product obtained during the preparation of technetium(III) boronic acid adducts of dioximes. The single crystal structure of TcCl(DMG)2(BDI)BEt (DMG=dimethylglyoxime, BDI=butane-2, 3-dione imine-oxime)

Abstract An unusual Tc(III) boron-capped imine-oxime complex has been isolated from the reaction of 99TcCl3(CH3CN)(PPh3)2, dimethyl glyoxime (DMG) and ethyl boronic acid (EtB(OH)2). A single crystal X-ray structure analysis of this molecule 99TcCl(DMG)2(BDI)BEt (BDI=butane-2, 3-dione imine-oxime) shows it to be seven coordinate: TcClC14H25N6O5B, a=9.073(2), b=23.686(5), c=19.539(6) A; β=93.77(2)°, P21/n, Z=8. Its structure is very similar to that of previously reported Tc(III) complexes 99TcCl(dioxime)3BR, except that one dioxime ligand on the molecule has been reduced to an imineoxime.

Studies towards understanding the mechanism of the unusual rearrangement of certain 5-propargyloxyindoles

Abstract A mechanism of the rearrangement of 5-propargyloxyindoles is proposed and supported by the formation of a novel tetracyclic indole derivative 12 as the major product in the cyclization of 5-propargyloxytryptophol 10 .

Cannabinoid CB1 receptor ligand binding and function examined through mutagenesis studies of F200 and S383

The cannabinoid CB(1) G protein-coupled receptor has been shown to be a regulator of food consumption and has been studied extensively as a drug target for the treatment of obesity. To advance understanding of the receptors three-dimensional structure, we performed mutagenesis studies at human cannabinoid CB(1) receptor residues F200 and S383 and measured changes in activity and binding affinity of compounds from two recently discovered active chemotypes, arylsulfonamide agonists and tetrahydroquinoline-based inverse agonists, as well as literature compounds. Our results add support to previous findings that both agonists and inverse agonists show varied patterns of binding at the two mutated residue sites, suggesting multiple subsites for binding to the cannabinoid CB(1) receptor for both functional types of ligands. We additionally find that an F200L mutation in the receptor largely restores binding affinity to ligands and significantly decreases constitutive activity when compared to F200A, resulting in a receptor phenotype that is closer to the wild-type receptor. The results downplay the importance of aromatic stacking interactions at F200 and suggest that a bulky hydrophobic contact is largely sufficient to provide significant receptor function and binding affinity to cannabinoid CB(1) receptor ligands.

Conformationally constrained calcium channel blockers: novel mimics of 1-benzazepin-2-ones.

In order to test a hypothesis that the seven-membered ring of the benzothiazepinone (diltiazem) and benzazepinone calcium channel blockers serves primarily to orient two critical pharmacophores in space, a series of novel, conformationally constrained bicyclo[2.2.2]octyl amines 3 which severely restrict the relative orientations available to the amine and methoxyphenyl groups was prepared. All compounds which positioned the pharmacophores on the same face of the molecule demonstrated vasorelaxant activity and affinity for the diltiazem receptor equal to or greater than racemic diltiazem 1 or the corresponding benzazepione 2. In addition, compound 3d was equipotent to (+)-diltiazem in its ability to reduce ischemic/reperfusion injury in an in vitro model of myocardial ischemia. However, 3d is significantly less cardiodepressive at an equivalent antiischemic dose. Therefore, the original receptor binding hypothesis led to the design and synthesis of novel calcium channel blockers with unique biological properties.

Confirmation of the structure of tetra-O-(tert-butyldimethylsilyl)-D-glucono-1,4-lactone formed by silylation of D-glucono-1,5-lactone.

The structure of tetra-O-(tert-butyldimethylsilyl)-D-glucono-1,4-lactone made by the silylation of D-glucono-1,5-lactone has been confirmed by single-crystal X-ray analysis.